Results 251 to 260 of about 785,489 (353)

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

Annals of Oncology, 2018
D. Westover, J. Zugazagoitia, B. Cho, C. Lovly, L. Paz-Ares   +4 more
semanticscholar   +1 more source

Non‐Destructively Quantifying the Whole‐Course Growth and Drug‐Response of PDOs by an Automatic Microfluidic System Utilizing Chemiluminescence Detection

Advanced Science, EarlyView.
The detection of secreted biomarkers enables molecular variations monitoring of organoid status. In this study, the non‐destructive quantification for the whole‐course growth and drug‐response of PDOs is first realized using a multifunctional microfluidic chip‐based system(ASMO) that integrates culturing, drug incubation, and biomarker detection ...
Yu Zhang, Daoyun Wang, Zhicheng Huang, Nan Zhang, Zhina Wang, Xin Wu, Anlan Zhang, Runzhi Yang, Tong Li, Zhibo Zheng, Yuxiao Lin, Naixin Liang, Zewen Wei   +12 more
wiley   +1 more source

Efficacy and safety of Chinese herbal medicine granules plus chemotherapy in patients with EGFR-mutated advanced lung adenocarcinoma post-progression on first-line EGFR-TKI: study protocol for a multicenter, double-blind, randomized controlled trial. [PDF]

BMC Complement Med Ther
Du Y, Yao J, Ye X, Wu G, Su L, Yang W, Jiao L, Gong Y, Xu L.   +8 more
europepmc   +1 more source

Marginal Stability of the YB1 Cold‐Shock Domain in Cells Enables Binding of Multiple Nucleic Acids

Advanced Science, EarlyView.
This study suggests that the marginal stability of the YB1 Cold‐Shock Domain (CSDex) allows for a balance between multifunctionality and conformational changes under physiological conditions. This balance is driven by the dynamic equilibrium between the unfolded ensemble (UE) and the native ensemble (NE) of CSDex (PDB:6LMR).
Puja Shrestha, Sara S. Ribeiro, Janne Aurich, Christian Herrmann, Simon Ebbinghaus   +4 more
wiley   +1 more source

Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis. [PDF]

BMC Cancer
Mei T, Wang T, Zhou Q.
europepmc   +1 more source

Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers

Advanced Science, EarlyView.
EGFR mutations drive ERK/c‐Jun–mediated transcriptional activation of CD73, elevating adenosine levels and fostering an immunosuppressive TME by impairing DC maturation and CD8⁺ T cell priming. The pH‐responsive nanodrug F127ZIF‐8AB680 selectively inhibits CD73, normalizes adenosine metabolism, and re‐establishes effective anti‐tumor immunity ...
Xiaoling Shang, Xudong Geng, Zixu Wang, Shumin Yuan, Shanshan Ding, Ni Liu, Xinchun Ma, Xuan Sun, Huimin Wang, Ying Sun, Xun Qu, Guangwen Ren, Yong Qiang Li, Xiuwen Wang, Yanguo Liu   +14 more
wiley   +1 more source

An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors

, 2020
Chao Cheng, Yanding Zhao, Evelien Schaafsma, Yi‐Lan Weng, Christopher I. Amos   +4 more
openalex   +2 more sources

INCIDENCE OF HEPATITIS B REACTIVATION DURING EGFR TYROSINE KINASE INHIBITORS TREATMENT IN NON‐SMALL‐CELL LUNG CANCER PATIENTS [PDF]

, 2018

openalex   +1 more source

TSH Ligand‐Based CAR‐T Cell Effectively Eradicates TSHR‐Positive Thyroid Cancer with Favorable Safety Profile

Advanced Science, EarlyView.
TSHR is highly expressed in differentiated thyroid cancer (DTC), making it an ideal target for adoptive immune cell therapy. A novel Ligand‐based TSH‐CAR‐T cell approach effectively eradicated TSHR‐positive thyroid tumors in vitro and accomplished full remission in tumor models with favorable safety profile, highlighting that TSH‐CAR‐T cells could ...
Fei Wang, Hui Zuo, Li Liu, Shiyuan Wang, Haifang Zhao, Zhao Liu, Gang Wang, Zhao Liu, Junnian Zheng, Chuan Xu, Hongwei Du   +10 more
wiley   +1 more source

Development and validation of a single-nephron estimated glomerular filtration rate model to predict disease progression in IgA nephropathy. [PDF]

BMC Nephrol
Yang C, Liang S, Duan ZY, Duan SW, Wu J, Feng Z, Chen P, Chen XM, Wang Y, Cai GY.   +9 more
europepmc   +1 more source